LAT2 and leukemia: Since our data showed that patients with high NTAL (and its interactors) expression exhibited similar genetic signature to this group of patients, it is conceivable that the treatment with menin–mixed lineage leukemia inhibitors may also work in this group of patients, even in the absence of NPM1/DNMT3A mutation.